Access and Evidence
Pharma and market access: How to overcome the challenges
Steven Flostrand, principal at IMS Consulting Group, on how to thrive in pharma’s difficult market environment
More Access and Evidence Articles
Access and Evidence
Dr. Bates’ Talkback: How to profitably compete in the oncology market
Dr. Andree K. Bates outlines key strategies for addressing the sales, marketing and market access challenges of the oncology market
Access and Evidence
New models for market access
Health economist Ulf Staginnus argues that pharma needs a lot more innovation—and a lot less outmoded market access discussions
Access and Evidence
Market access: How network intelligence increases value
Paolo Morgese of Merck Serono and Peter Wagner and Maximilian Schwarz of Mederi present 5 tips for matching stakeholders’ value expectations with demonstration of value
Access and Evidence
Market access: How to engage emerging stakeholders
Leela Barham reports on how the pharma industry can make the most of working with emerging stakeholders
Commercial
Pharma marketing and comparative effectiveness research
Rita E. Numerof explores what impact the use of comparative effectiveness research will have on the pharma and medical devices industries
Commercial
Merging market access with launch planning
Leela Barham looks at how bringing together launch and market access plans can increase the success of both
Commercial
Patients’ Week 2011: CER and the case for active patient engagement
Nathalie Horowicz-Mehler and John J Doyle explain why comparative effectiveness research (CER) must include patients’ perspectives on how to balance risk and benefit
Access and Evidence
Medical scientific liaisons: Sales reps in disguise?
Medical scientific liaisons (MSLs)—the people physicians talk to when they have scientific questions—have traditionally been separated from the marketing and commercial functions. Should the boundaries between the two functions be broken down?
Access and Evidence
Why oncology market access models must evolve
The proliferation of stakeholders makes oncology market access increasingly complexand successful models increasingly essential. Peter Mansell reports.